The supervisory board of AM-Pharma currently consists of the following individuals:
Prof. Eric Claassen PhD, Chairman of the Board, is Professor of Cellular Immunology/Immunomodulation at the Medical Faculty of the Erasmus University in Rotterdam.
Early in 2002, Eric Claassen was also appointed Professor “Entrepreneurship in Life Sciences” (BioPartner chair) at the Free University of Amsterdam. In addition, he is a director of Medifocus Lelystad B.V., a medical and biotech consultancy firm. Prior to that, he was Professor of the Veterinary Faculty of the University of Utrecht. Until 1 September 2001 he was Director of Research and deputy CEO at the Dutch Institute for Animal Science and Health. Prof. Claassen is an author of over 175 papers, more than 120 of which in peer reviewed journals, and an inventor of several patents.
Bart Bergstein is Managing Partner at Forbion Capital Partners.
Bart Bergstein holds a degree in construction engineering from the Technical University of Eindhoven. At ABN AMRO he has gained broad international experience in finance and business administration. Bart Bergstein has a seven years’ experience in Venture Capital. Furthermore he holds supervisory board positions in Seed Capital Investment Fund 2, Licentec, Ardana Biosciences (Edinburgh) and is executive member of the board of the BioPartner Facility Fund.
Ashok brings more than 20 years of international healthcare experience, focused primarily on Corporate & Business Development, Mergers & Acquisitions and Strategic Planning within leading multinational corporations where he was responsible for consumating a number of transformational deals and exits. His breadth of experience includes the unique opportunity of being involved in positions of significant influence across the sectors of functional foods, consumer health, pharmaceuticals and biotech. Additionally, he has built considerable network that enables global access to healthcare corporations, financial and high net worth communities.
Recent appointments comprise of Global Head of Corporate & Business Development at Serono, Senior Vice President and Global Head of Strategy and Business Development at Novartis Consumer Health; Vice President and Head of Strategy and Business Development at Baxter Europe, including senior positions at Roche, Andersen Consulting and Rhone-Poulenc. He holds a BA majoring in Economics & Commerce and a MBA from ESSEC. Ashok currently is Senior Vice President at Inventages Venture Capital and also serves as CEO and member of the board of directors at Horizon Science Pvt Ltd. Other board positions include Atonomics, Tanfield Foods, AM Pharma, ImmBio.
Frank Morich, MD, is Chief Executive Officer of Innogenetics.
Frank Morich, obtained a medical degree from the University of Marburg (Germany). After two years’ of post-doctoral research in immunology and cellular biology, he joined Bayer in 1982 and within the Pharmaceutical Division held roles such as Head of Research and Development as well as Head of Global Product Development. In 1998, he became the General Manager of Bayer AG’s Consumer Care Division. Two years later, he was promoted to be a member of the Boards of Bayer AG (Germany) and Bayer Corp. (United States). In 2002, he became the Chairman of the Board of Management and Executive Committee of the newly created Bayer Healthcare AG. Frank Morich was appointed Chief Executive Officer of Innogenetics on January 1, 2005. Prior to joining Innogenetics, he was CEO of AM Pharma. Frank Morich is currently a member of the Senate of Fraunhofer-Gesellschaft for Applied Research as well as a non-executive director of Innate Pharma (France).
For over 20 years David has been involved in the successful start up and development of commercial businesses in both executive and non executive/chairman roles. He was instrumental in the successful development of venture capital businesses at 3i and MVM and most recently was a member of the executive management team that transformed Evotec into a CNS focused drug discovery company through a series of M&A transactions.
David holds a BSc in Genetics & Zoology from Sheffield University.